𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evidence for a disorder of locomotor timing in Huntington's disease

✍ Scribed by Belinda Bilney; Meg E. Morris; Andrew Churchyard; Edmond Chiu; Nellie Georgiou-Karistianis


Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
86 KB
Volume
20
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Disturbances of walking have been described in people with Huntington's disease (HD), although the nature of the deficits have not yet been well defined. The purpose of this investigation was to determine whether people with HD have a deficit in the regulation of footstep timing during walking. The footstep patterns of 30 people with HD and 30 matched comparisons were measured at self‐selected slow, preferred, and fast speeds. Subjects were also instructed to match their footsteps to auditory metronome cues set at 80 and 120 beats per minute. Gait speed, cadence, stride length, and double limb support as a percentage of the gait cycle were measured using a computerized foot‐switch system. People with HD demonstrated a disorder in their ability to regulate cadence, manifest as a reduced step frequency when walking at preferred speed and when required to increase their speed. For all walking conditions, people with HD had increased variability of footstep cadence. They also had difficulty synchronizing their footstep timing to an auditory cue. For all walking conditions, people with HD had reduced stride length. Thus, in HD, there is a disorder in the regulation of footstep timing, with increased variability, a restricted cadence range, difficulty synchronizing footsteps to an auditory cue and reduced stride length. The exact neural correlates of this timing disorder are yet to be determined. © 2004 Movement Disorder Society


📜 SIMILAR VOLUMES


A futility study of minocycline in Hunti
✍ Dr. Merit Cudkowicz; The Huntington Study Group DOMINO Investigators 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract This study assessed the futility of proceeding with a Phase 3 clinical trial of minocycline as a disease‐modifying treatment for Huntington's disease (HD). One hundred fourteen research participants with HD were randomized, 87 to minocycline (200 mg/d) and 27 to placebo. The change in T

A controlled trial of remacemide hydroch
✍ Dr. Karl Kieburtz; Andrew Feigin; Michael McDermott; Peter Como; David Abwender; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 450 KB 👁 1 views

## Abstract We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate receptor ion‐channel blocker, remacemide hydrochloride, in 31 independently ambulatory patients (18 men, 13 women) with Huntington's disease (HD). Subjects were rand

A pilot study using nabilone for symptom
✍ Adrienne Curtis; Ian Mitchell; Smitaa Patel; Natalie Ives; Hugh Rickards 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and beha

Rate of change in early Huntington's dis
✍ Christina Meyer; Bernhard Landwehrmeyer; Carsten Schwenke; Adam Doble; Michael O 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

## Abstract Sensitive outcome measures for patients with Huntington's disease (HD) are required for future clinical trials. Longitudinal data were collected from a 3‐year study of 379 patients suffering from early HD who were not treated by antipsychotics. Progression of UHDRS item scores was evalu